| |
 |
Thrombotech exhibited at the ILSI-Biomed 2009, hosted by the Israel Life
Sciences Industry (ILSI),
which took place on June 15-17 in Tel Aviv, Israel. Thrombotech’s advances
in stroke treatment were also promoted by Hadassit at the the Bio International
Convention on May 18-21, 2009 in Atlanta, Georgia. |
Press coverage
Patience pays in biotech
Hadasit Bio Holdings allows investors access to early stage research.
Laura Goldman, Globes, 7 Oct 2008
http://markets.globes.co.il/serveen/globes/docview.asp?did=1000388562&fid=980 |
|
|
|
| |
Clal Biotechnology is strategic investor in Thrombotech
CBI will invest $50,000 in Thrombotech’s blood clot treatment.
Gali Weinreb, Globes, 8
Jan 2007
http://www.globes.co.il/DocsEn/did=1000170767.htm
Thrombotech to begin clinical trial of blood clot treatment
The company claims that its peptide can achieve its target as a stand alone drug without the need to be combined with
existing drugs on the market.
Batya Feldman, Globes, 19 Oct 2006
http://www.globes.co.il/serveen/globes/docview.asp?did=1000143727
Press releases
Lifesaving Treatment for Stroke Victims Developed by Thrombotech Ltd. : Hadassah-UPenn Team
Oct. 17, 2006
A Hadassah-University of Pennsylvania research team has developed a peptide that could save the lives and improve
the treatment of people stricken with ischemic strokes. Their findings, published recently in the prestigious medical journal,
Nature Neuroscience, indicate they have found a way to bypass the serious side effects of the thrombolytic agent tPA
(a medication that dissolves clotting). Currently, only about three percent of stroke victims can receive tPA, the only FDA-approved
treatment for acute ischemic stroke, because of the high incidence of post-treatment complications and the three-hour window when it is effective.
http://www.hbl.co.il/press_item.asp?ID=20
Hadasit Bio-Holdings Invests another NIS 700,000 in Thrombotech, One of its Portfolio Companies
Jun. 15, 2006
Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange symbol: HDST) announced today that it is continuing to apply the proceeds
of its public offering (January 2006) to investments in its subsidiaries and has invested approximately NIS 700,000 in its portfolio company Thrombotech.
According to Dr. Rafi Hofstein, CEO of Hadasit Bio-Holdings, “the investment in Thrombotech is an expression of our faith in the company’s success
during recent months in developing a treatment for stroke. Thrombotech has managed to demonstrate that it has a solution that can provide
excellent treatment for the severe side-effects of the drugs currently in use. Most of the drugs administered today, especially those developed by
Genentech (tPA), are effective, but in order to make sure that the patient is not exposed to the side-effects, characterized mainly by internal hemorrhage,
there is a narrow window for treatment, estimated at about three hours after the onset of the stroke. On the basis of the trials and findings in an animal model,
the drug being developed by Thrombotech can be expected to show similar effectiveness, but the window for administration will be longer,
up to nine hours after the event.”
http://www.hbl.co.il/press_item.asp?ID=8
Thrombotech Ltd., A Portfolio Company Of Hadasit Bio-Holdings Ltd., Reports New Findings At The Conclusion Of Animal Trials
May. 9, 2006
Tel Aviv, Israel, May 9, 2006. Hadasit Bio-Holdings Ltd. (TASE symbol: HDST) announced today that Thrombotech Ltd., one of its portfolio companies,
has concluded laboratory trials demonstrating that a peptide developed by the company, administered in combination with existing drugs for the
treatment of strokes or acute myocardial infarction (tPA, manufactured by Genentech), seems to prevent the side effects and hemorrhage and
significantly reduces the intracerebral hemorrhage that accompanies the drugs in use today. It was also found that this peptide may reduce the size of
necroses caused by the administration of the existing drugs by up to threefold.
http://www.hbl.co.il/press_item.asp?ID=5
|
|
| |
|
|
|
